Perspective Therapeutics, Inc.
Radiopharmaceutical cancer therapeutics using targeted isotope delivery
Follows are private to you and power your alerts
Updated · perspectivetherapeutics.com
- Sector
- Biotech
- Headquarters
- Seattle, WA
- Latest Form D
- $87.4M, Mar 2024
- Total capital
- $164M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $164M
- 4 Form D · last Mar 2024
- 31 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 16 pending · first 2025
- Rank in peer group#293 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$87.4M
- Private capital raisedForm D · SEC · 3rd filing$20.8M
- Private capital raisedForm D · SEC · 2nd filing$54.6M
- Private capital raisedForm D · SEC · 1st filing$729K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#293 · top 20%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Frank MorichDirectorNamed in SEC Form D filings
- Heidi HensonDirectorNamed in SEC Form D filings
- Jennifer StreeterExecutive OfficerNamed in SEC Form D filings
- Johan (Thijs) SpoorExecutive Officer, DirectorNamed in SEC Form D filings
- Jonathan HuntExecutive OfficerNamed in SEC Form D filings
- Lori WoodsDirectorNamed in SEC Form D filings
Show all 10 people
- Mark AustinExecutive OfficerNamed in SEC Form D filings
- Markus PuhlmannExecutive OfficerNamed in SEC Form D filings
- Michael McCormickDirectorNamed in SEC Form D filings
- Robert Williamson IIIDirectorNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 20- GrantedCHOLECYSTOKININ-2 Receptor Targeted Compounds And Use ThereofUSPTOUS 12,642,876
- GrantedSystems And Methods For Generating RadionuclidesUSPTOUS 12,570,539
- GrantedFibroblast Activation Protein Targeting PeptidesUSPTOUS 12,514,938
Show all 20 patent records
- CHOLECYSTOKININ-2 Receptor Targeted Compounds And Use ThereofJun 2, 2026 · US 12,642,876Granted
- Systems And Methods For Generating RadionuclidesMar 10, 2026 · US 12,570,539Granted
- Fibroblast Activation Protein Targeting PeptidesJan 6, 2026 · US 12,514,938Granted
- Systems And Methods For Generating RadionuclidesDec 4, 2025 · Application 19072755Pending
- Systems And Methods For Generating RadionuclidesDec 4, 2025 · Application 19065133Pending
- Systems And Methods For Generating LeadSep 4, 2025 · Application 19186044Pending
- Systems And Methods For Generating LeadMay 27, 2025 · US 12,312,653Granted
- Fibroblast Activation Protein Targeted Compounds And Use ThereofApplication PCTUS2024059811Pending
- Fibroblast Activation Protein Targeted Compounds And Use ThereofApplication PCTUS2024059813Pending
- System And Process For Generating Radium NuclideApplication 63706305Pending
- Conjugates for Targeted RadiotheranosticsApplication 63691293Pending
- Radionuclide Composition And Method Of Using Same For Detection Of Tumor CellsApplication 63690365Pending
- Systems And Methods For Generating LeadApplication PCTUS2024042524Pending
- Fibroblast Activation Protein Targeted Compounds And Use ThereofApplication PCTUS2024027190Pending
- System And Process For Generating Radium NuclideApplication PCTUS2025049478Pending
- Conjugates For Targeted RadiotheranosticsApplication PCTUS2025045196Pending
- Conjugates For Egfr Targeted RadiotheranosticsApplication PCTUS2025045187Pending
- Radionuclide Composition And Method Of Using Same For Detection Of Tumor CellsApplication 63807275Pending
- Fibroblast Activation Protein Targeted Compounds And Use ThereofApplication PCTUS2024059809Pending
- Fibroblast Activation Protein Targeted Compounds And Use ThereofApplication PCTUS2024059815Pending
Related companies, and why
- Volastra TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Eyconis, Inc.Similar federal contract value in Biotech · null in contracts
- Eikon TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Accent TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Affinia TherapeuticsSimilar federal contract value in Biotech · null in contracts
- PRECISION BIOSCIENCES INCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .